Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 73 pages report, published by Global Markets Direct

Keywords : Leishmaniasis (Kala-Azar) Therapeutic Products under Development, Key Players in Leishmaniasis (Kala-Azar) Therapeutics, Leishmaniasis (Kala-Azar) Pipeline Overview, Leishmaniasis (Kala-Azar) Pipeline, Leishmaniasis (Kala-Azar) Pipeline Assessment

Report ThumbnailSeptember-2013
Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar). Leishmaniasis (Kala-Azar) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Leishmaniasis (Kala-Azar).
- A review of the Leishmaniasis (Kala-Azar) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Leishmaniasis (Kala-Azar) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2013 9
  • Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H2 2013 10
  • Products under Development by Companies, H2 2013 11
  • Products under Investigation by Universities/Institutes, H2 2013 13
  • Late Stage Products, H2 2013 14
  • Early Clinical Stage Products, H2 2013 15
  • Discovery and Pre-Clinical Stage Products, H2 2013 16
  • Assessment by Monotherapy Products, H2 2013 28
  • Assessment by Route of Administration, H2 2013 29
  • Assessment by Stage and Route of Administration, H2 2013 30
  • Assessment by Molecule Type, H2 2013 31
  • Assessment by Stage and Molecule Type, H2 2013 32
  • List of Tables
  • Number of Products Under Development for Leishmaniasis (Kala-Azar), H2 2013 9
  • Products under Development for Leishmaniasis (Kala-Azar) - Comparative Analysis, H2 2013 10
  • Number of Products under Development by Companies, H2 2013 12
  • Number of Products under Investigation by Universities/Institutes, H2 2013 13
  • Comparative Analysis by Late Stage Development, H2 2013 14
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 15
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 16
  • Products under Development by Companies, H2 2013 17
  • Products under Investigation by Universities/Institutes, H2 2013 18
  • Merck KGaA, H2 2013 19
  • iCo Therapeutics Inc., H2 2013 20
  • AEterna Zentaris Inc., H2 2013 21
  • MOLOGEN AG, H2 2013 22
  • Advinus Therapeutics Pvt. Ltd., H2 2013 23
  • Pieris AG, H2 2013 24
  • Dafra Pharma International Ltd., H2 2013 25
  • aRigen Pharmaceuticals, Inc., H2 2013 26
  • Georgia Tech Research Corporation, H2 2013 27
  • Assessment by Monotherapy Products, H2 2013 28
  • Assessment by Stage and Route of Administration, H2 2013 30
  • Assessment by Stage and Molecule Type, H2 2013 32
  • Leishmaniasis (Kala-Azar) Therapeutics - Drug Profile Updates 62
  • Leishmaniasis (Kala-Azar) Therapeutics - Discontinued Products 64
  • Leishmaniasis (Kala-Azar) Therapeutics - Dormant Products 65
  • Table of Contents
  • Table of Contents 2
  • List of Tables 6
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Leishmaniasis (Kala-Azar) Overview 8
  • Therapeutics Development 9
  • An Overview of Pipeline Products for Leishmaniasis (Kala-Azar) 9
  • Leishmaniasis (Kala-Azar) Therapeutics under Development by Companies 11
  • Leishmaniasis (Kala-Azar) Therapeutics under Investigation by Universities/Institutes 13
  • Late Stage Products 14
  • Comparative Analysis 14
  • Early Clinical Stage Products 15
  • Comparative Analysis 15
  • Discovery and Pre-Clinical Stage Products 16
  • Comparative Analysis 16
  • Leishmaniasis (Kala-Azar) Therapeutics - Products under Development by Companies 17
  • Leishmaniasis (Kala-Azar) Therapeutics - Products under Investigation by Universities/Institutes 18
  • Companies Involved in Leishmaniasis (Kala-Azar) Therapeutics Development 19
  • Merck KGaA 19
  • iCo Therapeutics Inc. 20
  • AEterna Zentaris Inc. 21
  • MOLOGEN AG 22
  • Advinus Therapeutics Pvt. Ltd. 23
  • Pieris AG 24
  • Dafra Pharma International Ltd. 25
  • aRigen Pharmaceuticals, Inc. 26
  • Georgia Tech Research Corporation 27
  • Leishmaniasis (Kala-Azar) - Therapeutics Assessment 28
  • Assessment by Monotherapy Products 28
  • Assessment by Route of Administration 29
  • Assessment by Molecule Type 31
  • Drug Profiles 33
  • PRS-010 - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • amphotericin B - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • sitamaquine - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • amphotericin B - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • MGN-1331 - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • Oleylphosphocholine - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • LEISH-F3 GLA-SE Vaccine - Drug Profile 41
  • Product Description 41
  • Mechanism of Action 41
  • R&D Progress 41
  • AS-605240 - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • miltefosine - Drug Profile 44
  • Product Description 44
  • Mechanism of Action 44
  • R&D Progress 44
  • Neglected Diseases Program - Drug Profile 46
  • Product Description 46
  • Mechanism of Action 46
  • R&D Progress 46
  • Vaccine For Leishmania - Drug Profile 47
  • Product Description 47
  • Mechanism of Action 47
  • R&D Progress 47
  • amphotericin B NanoDisk - Drug Profile 48
  • Product Description 48
  • Mechanism of Action 48
  • R&D Progress 48
  • Isoxazole Containing Heteroretinoid And Amide Derivatives - Drug Profile 49
  • Product Description 49
  • Mechanism of Action 49
  • R&D Progress 49
  • Chalcone Derivatives - Drug Profile 50
  • Product Description 50
  • Mechanism of Action 50
  • R&D Progress 50
  • Drug For Parasitic Diseases - Drug Profile 51
  • Product Description 51
  • Mechanism of Action 51
  • R&D Progress 51
  • Drug For Cutaneous Leishmaniasis - Drug Profile 52
  • Product Description 52
  • Mechanism of Action 52
  • R&D Progress 52
  • Neglected Disease Program 1 - Drug Profile 53
  • Product Description 53
  • Mechanism of Action 53
  • R&D Progress 53
  • Neglected Disease Program 2 - Drug Profile 54
  • Product Description 54
  • Mechanism of Action 54
  • R&D Progress 54
  • Bisnaphthalimido Derivatives - Drug Profile 55
  • Product Description 55
  • Mechanism of Action 55
  • R&D Progress 55
  • Nonpeptide Macrocyclic Histone Deacetylase (HDAC) Inhibitors - Drug Profile 56
  • Product Description 56
  • Mechanism of Action 56
  • R&D Progress 56
  • Drugs For Leishmaniasis - Drug Profile 57
  • Product Description 57
  • Mechanism of Action 57
  • R&D Progress 57
  • S-010-265 - Drug Profile 58
  • Product Description 58
  • Mechanism of Action 58
  • R&D Progress 58
  • S-010-269 - Drug Profile 59
  • Product Description 59
  • Mechanism of Action 59
  • R&D Progress 59
  • CDRI-99/288 - Drug Profile 60
  • Product Description 60
  • Mechanism of Action 60
  • R&D Progress 60
  • Compound-2d - Drug Profile 61
  • Product Description 61
  • Mechanism of Action 61
  • R&D Progress 61
  • Leishmaniasis (Kala-Azar) Therapeutics - Drug Profile Updates 62
  • Leishmaniasis (Kala-Azar) Therapeutics - Discontinued Products 64
  • Leishmaniasis (Kala-Azar) Therapeutics - Dormant Products 65
  • Leishmaniasis (Kala-Azar) - Product Development Milestones 66
  • Featured News & Press Releases 66
  • Jun 19, 2013: Paladin Receives Priority Review Status From FDA For Impavido NDA Submission For Treatment Of Leishmaniasis 66
  • Dec 17, 2012: PATH’s Drug Development Program Announces Successful Completion Of Phase IIIb Clinical Trial Of Paromomycin Intramuscular Injection In Bangladesh 66
  • Jun 26, 2012: Leishdnavax Consortium Successfully Concludes Preclinical Development Of MGN1331 DNA Vaccine Against Leishmaniasis 67
  • Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis 68
  • Jan 09, 2012: Study Confirms New Strategy In Fight Against Infectious Diseases 69
  • Oct 24, 2011: iCo Therapeutics Oral Amphotericin B Delivery System To Be Presented At AAPS 70
  • Sep 29, 2010: iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status 70
  • Apr 06, 2010: MOLOGEN AG Receives Funding To Develop A DNA Vaccine Against Hepatitis B 71
  • Appendix 72
  • Methodology 72
  • Coverage 72
  • Secondary Research 72
  • Primary Research 72
  • Expert Panel Validation 72
  • Contact Us 73
  • Disclaimer 73

Please select a license type

Share

Related Products

Global Markets DirectLeishmaniasis (Kala-Azar) - Pipeline Review, H2 2013Product ThumbnailLeishmaniasis (Kala-Azar) - Pipeline Review, H2 2013, Industry ReportProduct #: 113298
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved